Quebec Health Minister Christian Dubé announces the introduction of a significant preventive measure to protect vulnerable infants and young children against complications of respiratory syncytial virus (RSV).
Starting in the fall of 2024, nirsévimab (Beyfortus™), a new preventive medication, will be administered free of charge to babies at risk in Quebec, making this province the first in Canada to offer this treatment free of charge.
Nirsevimab will be administered by a single intramuscular injection, making it simple and effective for families to use. This medication is specifically designed to reduce the risk of severe complications from RSV, which can lead to hospitalization. The introduction of this treatment is a considerable step forward in the fight against this seasonal virus which mainly affects children and can lead to bronchiolitis or serious pneumonia.
Distribution and eligibility criteria
The first deliveries of nirsevimab are scheduled for early September 2024. The treatment will be available in health and social services establishments across Quebec. It will be given to infants who are:
• Less than 6 months old at the start of the RSV season or born during the season;
• Having health conditions that expose them to increased risks of complications, such as prematurity or heart or lung disease.
Parents are encouraged to discuss with their child’s healthcare professional to determine if their baby is eligible to receive nirsevimab.
Implications for the health system
The adoption of nirsevimab is seen not only as protection for vulnerable children but also as a strategy to reduce pressure on health services during the autumn and winter months, typical periods of RSV circulation.
Statement from the Minister of Health
“The addition of nirsevimab to our prevention arsenal is a major step forward for public health,” says Christian Dubé. “This free treatment will provide additional peace of mind to Quebec families and will help reduce the number of hospitalizations and medical consultations due to RSV. »
For more information on access to nirsevimab and distribution criteria, parents and health professionals can consult the detailed guidelines published by the National Institute of Excellence in Health and Social Services, available on the List of medications from establishments at the address https://www.ramq.gouv.qc.ca/fr/a-propos/liste-medicaments-fournis-etablissement.
Source: Office of the Minister of Health / CNW
Publication Health Index: 2024-05-24
Number of visits since publication: 13
Read on Health Index:
 for infants in Quebec){kind=link}